These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17346159)

  • 21. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
    Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Imatinib].
    Urabe A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Molecular therapy of breast carcinoma in the advanced phase].
    Foggi P; Amodio A
    Tumori; 2003; 89(4 Suppl):189-91. PubMed ID: 12903589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ; Vanderhyden BC
    Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
    Borg C; Terme M; Taïeb J; Ménard C; Flament C; Robert C; Maruyama K; Wakasugi H; Angevin E; Thielemans K; Le Cesne A; Chung-Scott V; Lazar V; Tchou I; Crépineau F; Lemoine F; Bernard J; Fletcher JA; Turhan A; Blay JY; Spatz A; Emile JF; Heinrich MC; Mécheri S; Tursz T; Zitvogel L
    J Clin Invest; 2004 Aug; 114(3):379-88. PubMed ID: 15286804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.
    Pierobon M; Silvestri A; Spira A; Reeder A; Pin E; Banks S; Parasido E; Edmiston K; Liotta L; Petricoin E
    J Proteome Res; 2014 Jun; 13(6):2846-55. PubMed ID: 24787230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of clinical efficacy of imatinib in metastatic melanoma.
    Ugurel S; Hildenbrand R; Zimpfer A; La Rosée P; Paschka P; Sucker A; Keikavoussi P; Becker JC; Rittgen W; Hochhaus A; Schadendorf D
    Br J Cancer; 2005 Apr; 92(8):1398-405. PubMed ID: 15846297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
    Yoshida C; Niiya K; Niiya M; Shibakura M; Asaumi N; Tanimoto M
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):425-33. PubMed ID: 17581316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW; Honsawek S; Litz J; Buchdunger E
    Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The diagnostic and predictive role of kit (CD117)].
    Dirnhofer S; Zimpfer A; Went P
    Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting tyrosine kinases in cancer: the second wave.
    Baselga J
    Science; 2006 May; 312(5777):1175-8. PubMed ID: 16728632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
    Maulik G; Bharti A; Khan E; Broderick RJ; Kijima T; Salgia R
    J Environ Pathol Toxicol Oncol; 2004; 23(4):237-51. PubMed ID: 15511212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PDGF receptors as targets in tumor treatment.
    Ostman A; Heldin CH
    Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
    George D
    Adv Exp Med Biol; 2003; 532():141-51. PubMed ID: 12908555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.